Epigenetic Mutations as Markers of Clonal Evolution and Potential Guides for Therapy Selection in Ph-Negative Myeloproliferative Neoplasms (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-234; Location: LEVEL 3, HALL B3; "Among patients with PMF not treated with ruxolitinib, epigenetic mutations were associated with significantly worse OS (median, 5.3 vs 15.2 years; P = 0.006)... Epigenetic mutations represent markers of clonal evolution and are associated with a more aggressive disease phenotype in MPNs. Their co-occurrence with spliceosome mutations indicates advanced clonal complexity for PMF. These alterations identify a high-risk subgroup of patients and may guide therapeutic stratification, including selection of patients who may benefit from Janus kinase inhibitor therapy."
Tumor mutational burden • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • ARID1A • ASXL1 • CALR • CREBBP • DDX3X • DNMT3A • EP300 • IDH1 • IDH2 • JAK2 • PHF6 • SF3B1 • SRSF2 • SUZ12 • TET2 • TMB • U2AF1 • ZRSR2
|
|
Anna Kirienko PhD; Ekaterina Motyko PhD; Daria Kustova MSc; Irina Leppyanen PhD; Kira Ivanova PhD; Elizaveta Efremova MD; Irina Martynkevich DSc
|